FDA Office of Hematology and Oncology Products is now Office of Oncologic Diseases

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The Office of Hematology and Oncology Products at FDA has been renamed the Office of Oncologic Diseases—a move that includes an internal reorganization of divisions, as part of modernization plans approved in September 2019.

To access this subscriber-only content please log in or renew your subscription.

Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.

Login Subscribe
Matthew Bin Han Ong
Senior Editor

YOU MAY BE INTERESTED IN

Matthew Bin Han Ong
Senior Editor

Login